A novel signature to predict the neoadjuvant chemotherapy response of bladder carcinoma: Results from a territory multicenter real-world study

A novel signature to predict the neoadjuvant chemotherapy response of bladder carcinoma: Results from a territory multicenter real-world study

Background: Although neoadjuvant chemotherapy (NAC) has become the standard treatment option for muscle invasive bladder carcinoma (MIBC), its application is still limited because of the lack of biomarkers for NAC prediction.Methods: We conducted a territory multicenter real-world study to summarize...

Full description

Bibliographic Details
Main Authors: Huihuang Li, Jiao Hu, Xiongbing Zu, Minfeng Chen, Jinbo Chen, Yihua Zou, Ruoping Deng, Gang Qin, Wenze Li, Jiansheng Tang, Dingshan Deng, Jinhui Liu, Chunliang Cheng, Yu Cui, Zhenyu Ou
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Genetics
Subjects:
bladder carcinoma
neoadjuvant chemotherapy
pathological response
personalized therapy
risk score
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2022.1047481/full

Similar Items

Similar Items